Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Asset Writedowns and Impairment: 2011-2024

Historic Asset Writedowns and Impairment for Niagen Bioscience (NAGE) over the last 10 years, with Dec 2024 value amounting to -$1.3 million.

  • Niagen Bioscience's Asset Writedowns and Impairment fell 200.00% to -$12,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 3437.18%. This contributed to the annual value of -$1.3 million for FY2024, which is 234.85% down from last year.
  • Niagen Bioscience's Asset Writedowns and Impairment amounted to -$1.3 million in FY2024, which was down 234.85% from $964,000 recorded in FY2023.
  • Niagen Bioscience's Asset Writedowns and Impairment's 5-year high stood at $964,000 during FY2023, with a 5-year trough of -$1.3 million in FY2024.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $63,000 (2022), whereas its average is -$91,000.
  • Per our database at Business Quant, Niagen Bioscience's Asset Writedowns and Impairment surged by 1,430.16% in 2023 and then crashed by 234.85% in 2024.
  • Over the past 5 years, Niagen Bioscience's Asset Writedowns and Impairment (Yearly) stood at $36,000 in 2020, then increased by 27.78% to $46,000 in 2021, then surged by 36.96% to $63,000 in 2022, then skyrocketed by 1,430.16% to $964,000 in 2023, then plummeted by 234.85% to -$1.3 million in 2024.